PhaseBio Pharmaceuticals Inc.: Clinical Trials

7 completed. 7 Phase 1, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	7	Completed 7
Phase 2	1	Completed 1

Follow PhaseBio Pharmaceuticals Inc.: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH PB1046 Subcutaneous Injection - Pulmonary Arterial Hypertension	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	3	2017-10-20	2019-10-08
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046) - Essential Hypertension	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	20	2013-06-01	2014-04-10
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus PE0139 Injection, Placebo - Type 2 Diabetes Mellitus (T2DM)	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	37	2013-04-01	2014-10-15
Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus Single Dose PB1023 - Diabetes Mellitus, Type 2	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	10	2012-02-01	2012-10-01
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension Vasomera (PB1046), 0.9% Sodium Chloride - Essential Hypertension	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	68	2012-01-01	2013-01-04
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function PB1023 Injection - Diabetes Mellitus, Type 2	Phase 1	Completed	PhaseBio Pharmaceuticals Inc.	16	2011-12-01	2013-04-15
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl) - Diabetes Mellitus, Type 2	Phase 1 / Phase 2	Completed	PhaseBio Pharmaceuticals Inc.	80	2010-11-01	2013-05-21

Conditions studied

Diabetes Mellitus, Type 2 (4)  ·  Essential Hypertension (2)  ·  Hypertension (1)  ·  Pulmonary Arterial Hypertension (1)

Interventions

VIP-ELP fusion molecule PB1046 (2)  ·  Injections, Subcutaneous (1)  ·  Sodium Chloride (1)

Countries

United States (7)

Top investigators

Mark Matson, M.D. (2)  ·  Daniel K. Ries, MD (1)  ·  Mark Matson, MD (1)  ·  Ronald Brazg, MD (1)  ·  William B. Smith, MD (1)